Trevi Therapeutics, Inc. (NASDAQ:TRVI) Insider Thomas Sciascia Sells 18,660 Shares

Trevi Therapeutics, Inc. (NASDAQ:TRVI) insider Thomas Sciascia sold 18,660 shares of the business’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $2.76, for a total value of $51,501.60. Following the completion of the sale, the insider now directly owns 220,315 shares of the company’s stock, valued at $608,069.40. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Thomas Sciascia also recently made the following trade(s):

• On Wednesday, August 14th, Thomas Sciascia sold 100 shares of Trevi Therapeutics stock. The stock was sold at an average price of $2.75, for a total value of $275.00.
• On Wednesday, May 29th, Thomas Sciascia sold 53,368 shares of Trevi Therapeutics stock. The shares were sold at an average price of $2.55, for a total value of $136,088.40.

Trevi Therapeutics Price Performance

TRVI traded up $0.02 on Friday, hitting $2.77. The company had a trading volume of 75,730 shares, compared to its average volume of 243,420. Trevi Therapeutics, Inc. has a 52-week low of $0.97 and a 52-week high of $4.00. The stock has a fifty day simple moving average of $2.78 and a 200-day simple moving average of $2.74. The firm has a market capitalization of $195.10 million, a P/E ratio of -8.09 and a beta of 1.00.

Trevi Therapeutics (NASDAQ:TRVI) last announced its earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). During the same quarter last year, the company earned ($0.07) EPS. Equities research analysts expect that Trevi Therapeutics, Inc. will post -0.42 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Trevi Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Ally Bridge Group NY LLC bought a new stake in shares of Trevi Therapeutics during the second quarter valued at approximately $4,395,000. Opaleye Management Inc. increased its position in shares of Trevi Therapeutics by 48.6% during the fourth quarter. Opaleye Management Inc. now owns 2,535,000 shares of the company’s stock valued at $3,397,000 after acquiring an additional 829,100 shares in the last quarter. Logos Global Management LP grew its position in Trevi Therapeutics by 27.3% in the 2nd quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock worth $8,344,000 after purchasing an additional 600,000 shares during the period. Frazier Life Sciences Management L.P. grew its position in Trevi Therapeutics by 7.3% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 7,381,090 shares of the company’s stock worth $9,891,000 after purchasing an additional 500,000 shares during the period. Finally, Rosalind Advisors Inc. boosted its stake in shares of Trevi Therapeutics by 50.3% during the 2nd quarter. Rosalind Advisors Inc. now owns 1,391,577 shares of the company’s stock worth $4,147,000 after acquiring an additional 465,561 shares during the last quarter. Institutional investors own 95.76% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Rodman & Renshaw assumed coverage on Trevi Therapeutics in a research note on Thursday, June 13th. They issued a “buy” rating and a $7.00 target price on the stock. Needham & Company LLC restated a “buy” rating and set a $8.00 price target on shares of Trevi Therapeutics in a research report on Wednesday, May 8th.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.